Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Edwards org | History Defined

Is Edwards Lifesciences Stock Underperforming the Nasdaq?

Despite trailing the broader Nasdaq Composite over the last 12 months, Edwards Lifesciences continues to earn strong support from analysts.

Barchart

AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management. Speaking at a Bank of America fireside

MarketBeat

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

How Is Edwards Lifesciences’ Stock Performance Compared to Other Medical Device Stocks?

Edwards Lifesciences has notably outperformed the broader market over the past year, and analysts remain bullish on the stock’s prospects.

Barchart

Edwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector?

As Edwards Lifesciences outshines the broader healthcare sector, Wall Street remains optimistic about its prospects.

Barchart

3 Healthcare Pathbreakers With Long-Term Tailwinds

These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.

MarketBeat

FTC Sounds Alarm On Edwards' Attempt To Corner Heart Device Market

The Federal Trade Commission (FTC) on Wednesday moved to block medical device supplier Edwards Lifesciences Corp.'s (NYSE:EW) proposed acquisition of JenaValve Technology, Inc.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance

Edwards Lifesciences’ (NYSE:EW) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.

Benzinga

Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results

Edwards Lifesciences Corporation (NYSE:EW) reported better-than-expected second-quarter financial results on Thursday.

Benzinga

Is Edwards Lifesciences Stock Underperforming the S&P 500?

Edwards Lifesciences has recently underperformed the broader S&P 500, yet analysts remain moderately optimistic about the stock's potential.

Barchart

Edwards Lifesciences Outlines Vision For Growth At Investor Conference

Edwards Lifesciences outlines 2025 growth strategy, emphasizing innovations in TAVR and TMTT therapies, with a projected sales growth of 8%-10% and expanded patient care.

Benzinga

Secrets, legends and new places: six influencers talk about what makes Newcastle great

Looking for some new places to explore and fun things to do in and around Newcastle this year?

Newcastle Herald

Food Bites: Myrtle & Stone cafe helps Wollombi flood appeal

Plus, party time at Modus Merewether, LC Deli, FogHorn Brewery's final pop-up at the footy, Bottomless Bird, and it's your last chance to buy tickets to Thursday night's Four Pillars Gin Dinner at The Edwards.

Newcastle Herald

Distillery cans award-winning King Edward vodka as a summer spritz

Elsham Wold Distillery launches two flavours in on-trend ready-to-drink format

Birmingham Post

Get all your
news in one place.

100's of premium titles.
One news app.

Newcastle Herald

Food Bites: Crystalbrook Kingsley in Newcastle to host An Evening of Dreaming

The Roundhouse has a new executive chef, meet Paterson Tavern's new owners, and more foodie news.

StockNews.com

Abbott Laboratories vs. Edwards Lifesciences: Which Medical Device Stock is a Better Investment?

The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)…

Newcastle Herald

Silverchair's Chris Joannou sells The Edwards site for over $4 million

The sale will not affect the day-to-day running of the venue.

Newcastle Herald

Food Bites: Chinese cooking is a labour of love for The Edwards' head chef Jess Brooks

She will be cooking up a storm at Sunday night's Chinese BANGquet. Plus, Pampa Flame, Maitland Taste Festival, a cookbook to give away, and more foodie news.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery

The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) Mitris Resilia valve, a tissue valve replacement specifically designed for the heart's mitral position.

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.